Authors, year and country | Study population | No of participants/no of HIV seroconversions | HIV detection method | TV detection method | Main finding |
Delany-Moretlwe et al, 16 2011, South Africa | HIV-negative women | 2451/110 | Not stated | Not stated | Baseline TV+ more likely to seroconvert compared with TV−. IRR 2.3 (95% CI 1.1 to 4.9). |
Ghys et al, 17 2001, Ivory Coast | FSW HIV negative | 284/26 | ELISA+WB | Wet prep | TV+ women more likely to seroconvert than TV−. aRR* 2.8 (95% CI 1.3 to 6.2). |
Hester and Kennedy,18, 2003, Zambia | Women (serodiscordant couples) | 90/45 | Dot-WB | Wet prep | HIV acquisition among TV+ women at baseline compared with TV− women at baseline. OR 0.35 (95% CI 0.16 to 0.76). |
Kinuthia et al, 19 2015, Kenya | Women at a prenatal clinic | 1304/25 | NAATs | Wet prep | HIV acquisition for women with TV. aHR 1.14 (95% CI 0.16 to 8.16). |
Kleinschmidt et al, 14 2007, South Africa | Women attending FP clinics | 551/23 | HIV rapid test | Culture (Daimonds) | TV+ women more likely to acquire HIV-1 than TV− women. aHR 4.79 (95% CI 1.01 to 22.78). |
Laga et al,3 1993, Democratic Republic of Congo | FSW HIV negative | 431/68 | EIA+WB | Wet prep | TV+ women more likely to seroconvert than TV− women. AOR 1.9 (95% CI 0.9 to 4.1). |
Laga et al,20 1994, Democratic Republic of Congo | FSW HIV negative | 531/70 | EIA+WB | Wet prep | TV+ women more likely to seroconvert than TV− women. RR 1.7 (95% CI 1.1 to 2.8). |
Martin et al,21 1998, Kenya | FSW HIV negative | 799/111 | EIA | Wet prep | HIV acquisition for FSW with TV. aHR 1.2 (95% CI 0.7 to 2.2) |
Masese et al,22 2015, Kenya | FSW HIV negative | 1964/325 | EIA | Wet prep | HIV acquisition for FSW with TV. aHR 1.41 (95% CI 0.99 to 2.02). |
Mavedzenge et al,23 2010, Zimbabwe and South Africa | Women (general population) | 4948/309 | HIV rapid, EIA | NAATs | HIV acquisition with those with TV. aHR 2.05 (95% CI 1.05 to 4.02) |
McClelland et al,24 2005, Kenya | FSW | 1215/238 | EIA | Wet prep | HIV acquisition for FSW with TV. HR 1.3 (95% CI 1.0 to 1.7). |
McClelland et al,25 2007, Kenya | FSWs HIV-1–seronegative | 1335/261 | EIA | Wet prep | HIV acquisition for FSW with TV. aHR 1.52 (95% CI 1.04 to 2.24). |
Myer et al,26 2006, South Africa | Women (general population) | 3570/85 | Abbott HIV 1/2 Kit | Wet prep | Baseline TV +women more likely to seroconvert than TV− women. cHR 1.84 (95% CI 1.02 to 3.32). |
Nagot et al,27 2005, Burkina Faso | FSW | 377/19 | EIA | Wet prep | HIV acquisition for FSW with TV. HR 0.71 (95% CI 0.22 to 2.29). |
Quinn et al,28 2000, Uganda | Serodiscodant couples | 414/90 | EIA+WB | Culture (InPouch) | HIV acquisition when a person has TV. aRR* 1.27 (95% CI 0.65 to 2.35). |
Taha et al,29 1998, Malawi | HIV-negative postnatal women | 1196/124 | EIA+WB | Wet prep | TV+ women more likely to seroconvert than TV– women. aRR 1.38 (95% CI 0.75 to 2.56). |
Van De Wijgert et al,30 2009, Zimbabwe and Uganda | Women at FP and mother–child health clinics | 4439/189 | ELISA, confirmed by rapid test or PCR or WB | Wet prep | TV associated with HIV if it is detected in current and previous visit to HIV seroconversion. aHR 1.53 (95% CI 0.21 to 11.01). |
Van Der Pol et al,13 2008, Uganda and Zimbambwe | FP clinic and FSW HIV− | 4531/213 | NAATs | Wet prep and NAATs | TV+ women at previous visit were more likely to seroconvert than women without TV. AOR 2.74 (95% CI 1.25 to 6.00) FP &FSW AOR 3.3 (95% CI 1.36 to 7.85) FP only. |
Vandepitte et al,31 2013, Uganda | FSW | 646/42 | HIV rapid, confirmed by ELISA | Culture | TV increase likelihood of HIV acquisition with aHR 2.72 (95% CI 1.27 to 5.84). |
All studies were cohort studies, except Hester & Kennedy18 (2003) and Laga et al.3 (1993), which were nested case-control studies. Studies are arranged alphabetically according to the name of the first author and then year of publication.
aHR, adjusted HR; AOR, adjusted OR; aRR*, adjusted rate ratio; ARR, adjusted risk ratio; cHR, crude hazard ratio; EIA, enzyme immunoassay; FP, family planning; FSW, female sex workers; IRR, independent risk ratio; NAATs, Nnucleic acid amplification tests; TV, Trichomonas vaginalis; WB, western blot.